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Summary The epidemiology of invasive meningococcal disease varies geographi-
cally and in time and the risk of acquiring the disease varies regionally, as well as
with living conditions and behavior. An area, in which meningococcal disease out-
breaks have frequently occurred, is the ‘‘African meningitis belt’’, where epidemics
of meningococcal disease with a peak incidence as high as 100—800/100,000 popu-
lation/year have been reported. Another risk factor is mass gatherings including the
Islamic pilgrimage to Makkah (Mecca), where outbreaks of meningococcal disease
have repeatedly occurred. The latest outbreaks occurred during the Hajj pilgrim-
ages of 2000 and 2001, when a shift from serogroup A disease to serogroup W135
occurred. Vaccination against serogroups A, C, W-135 and Y with novel conjugate
vaccines may help protect individuals and reduce the spread of bacterial carriage
and disease. Individuals who should be vaccinated include travelers to epidemic
or hyperendemic areas (as identiﬁed by international health authorities), travelers
for Umra or Hajj (Hajj pilgrims), travelers to high risk countries or regions (African
meningitis belt) during the dry season or countries in sub-Saharan Africa outside the
meningitis belt (where outbreak of meningitis has been reported in the preceding
2—3 years), military recruits or deployed military personnel, immunocompromized
travelers and high school and college students. This review presents the global epi-
demiology of meningococcal disease, and discusses prophylaxis options including
meningococcal ACWY vaccines.
© 2010 Published by Elsevier Limited on behalf of King Saud Bin Abdulaziz University
for Health Sciences. All rights reserved.ontents
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The traveler’s risk
Over the past 200 years, epidemic outbreaks of
meningococcal disease have occurred in Europe,
Africa, Asia, the United States and New Zealand
[1]. The epidemiology of meningococcal disease is
dynamic and variable because the distribution of
the serogroups triggering invasive disease varies,
both in terms of their geographical distribution and
their occurrence in time.
Constantly growing international travel has the
potential to accelerate the intercontinental spread
of the various serogroups. While serogroup A, and to
a lesser extent serogroup C, was originally respon-
sible for most epidemics (mainly in Africa), recent
years have seen increasing attention being focused
on the serogroup W135 (Saudi Arabia, West Africa).
Serogroup B is the most important cause in indus-
trialized countries of Europe and America as well as
in the Asian-Paciﬁc region. Currently, serogroup Y
is becoming ever more prevalent in some countries,
and serogroup X has occasionally been observed in
Africa. Thus, these serogroups are gaining in impor-
tance.
Since the incidence of meningococcal infections
in travelers is appreciably lower than that of other
preventable diseases (for example, hepatitis A,
inﬂuenza, typhoid fever), the risk of infection with
invasive meningococci is generally neglected.
Worldwide, the annual rate of invasive meningo-
coccal infections is approximately 500,000 cases,
resulting in 50,000 deaths. Surprisingly, it is often
forgotten that a local outbreak can also endanger
tourists [2].
The risk of a traveler acquiring an infection with
meningococci is present throughout the world, but
varies depending on the epidemiological situation.
In view of the severity of the disease (mortality
rate approximately 10%, persistent health problems
approximately 20%), the risk of a traveler contract-
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ng a severe meningococcal infection should not be
nderestimated [2]. The volume of international
ravel is constantly expanding. In 2007, the number
f travelers increased by 52 million (+6%), com-
ared with 2006. By the year 2020, international
ravel is expected to increase to 1.6 billion, includ-
ng 378 million long-distance travelers. In 2007, the
reatest increase in international travel was seen
n the Middle East (+13%), the Asia-Paciﬁc region
+10%), and Africa (+8%) [3]. Africa and the Middle
ast are also the regions with the highest rate of
eningococcal disease [2].
Since the infection is transmitted via respiratory
roplets, the risk may vary depending on envi-
onmental conditions. Such conditions as crowded
reas, a dry atmosphere, individual state of health,
moking, duration of exposure to infected persons
nd the behavior of the traveler in the country
isited are of primary importance. The risk of
ecoming infected increases with the incidence of
isease in the country visited, and is elevated when
ravelers seek close contact with the local popula-
ion.
Furthermore, travelers can be potential asymp-
omatic carriers of meningococci. As such, they
ay become infected and introduce meningococ-
al serogroups into their home countries that have
ot been endemic there. In fact, this has been
emonstrated to occur by pilgrims returning from
ajj spreading the bacteria and causing invasive
eningococcal disease in contact persons [4].
he geographical riskfrica
ost epidemics in Africa were caused by the
erogroup A with serogroup W135 as the second
ost common cause. The risk of infection is great-
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mFigure 1 The meningitis belt in Africa.
ource: WHO [39].
st in the so-called meningitis belt extending from
enegal in the west to Ethiopia in the east (Fig. 1).
n this region, epidemics occur at regular inter-
als (approximately every 10—15 years), with a
eak incidence as high as 100—800/100,000 pop-
lation/year. Nigeria is a recent example of a
eningococcal epidemic: at the end of April 2009,
ore than 56,000 infections, with 1900 fatalities,
ere reported, with predominace of serogroup A
5]. Overall, the meningitis belt appears to be
xtending, with regions outside the belt also expe-
iencing epidemics (Burundi, Rwanda, Republic of
anzania, Niger). Between 2007 and 2008, the
erogroup W135, which had previously triggered
nly sporadic cases in West and Central Africa, was
esponsible for 57 cases [6], and in the spring of
009 caused an epidemic in Chad [7]. In contrast,
ther regions (Mali, Sudan) have seen no signiﬁcant
ncrease in the number of cases of meningococcal
isease for more than 10 years. In Niger the emer-
ence of serogroup X has been reported [8].
outh Africa
pidemiological studies show that between 1992
nd 1997, the majority of cases were caused by
erogroup A. In the period 2000—2005, cases caused
y serogroup W135 increased from 5% in 2000
o 62% in 2005. The incidence increased from
.54/100,000 in 2000 to 1.6/100,000 in 2005. At
he same time, the incidence of serogroup A dis-
A
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ase decreased, while that of serogroup Y remained
table [9].
iddle East/Saudi Arabia
ere, serogroups A, C and W135 predominate. The
slamic Hajj pilgrimage to Makkah (Mecca) is asso-
iated with a high risk of infection. The very large
umbers of people (some two million pilgrims from
ll over the world) crowded together within a
imited space, increases the transmission rate of
nfection enormously (Fig. 2). The carrier rates in
akkah, the city holding the Holy Mosque, may be
s high as 80% [2,10]. However, various investiga-
ions have found different carriage rates after Hajj.
hile an unexpected low percentage was detected
n a small surveillance study from Saudi Arabia [11],
nother study from the US CDC, investigating pil-
rims from the US on their journey home after Hajj,
ound a rate of 11% of pilgrims positive for meningo-
occal carriage [12].
In the years 1987, 1992, 2000 and 2001, out-
reaks occurred among the Hajj pilgrims in Makkah
nd also in their home countries — triggered by
he carriage back home of meningococci acquired
n Makkah. The incidence in the high risk group of
ajj pilgrims was up to 640/100,000 persons [12].
hile before 2000 outbreaks were associated with
erogroup A, in 2000 and 2001 serogroup W135 was
redominant. The outbreaks underscore the risk
f various serogroups being transmitted as well as
llustrate the danger of introducing previously very
are serogroups into other parts of the world.
In 2002, as a consequence of the emergence
f serogroup W135, Saudi Arabia changed the
accination recommendation from bivalent A/C
olysaccharide vaccine (which from 1988 on had
een compulsory for the issue of Hajj pilgrimage
isas) to compulsory vaccination with a quadriva-
ent ACWY meningococcal polysaccharide vaccine
or visitors/pilgrims entering the country during the
ajj season. Since this measure was put in place,
he number of infections has decreased appre-
iably. Since 2002 no outbreaks of meningococcal
isease have occurred [13]. However, polysaccha-
ide vaccines are regarded as T cell independent
ntigens. Their use does not reliably reduce the
arrier rate (as systemically reviewed by Dellicour
nd Greenwood [14]), so that the risk remains that
eturning asymptomatic pilgrims can still introduce
eningococci into their home countries (Fig. 3).sia
erogroups A and C predominate. Between 1982 and
984 Nepal experienced an outbreak of serogroup
146 Z.A. Memish et al.
ns at
(
dFigure 2 Crowded conditio
Source: [40].
A infections, with more than 4500 cases. Six trav-
elers became infected, two of whom died. The
fatalities were tourists who had had close contact
with the local population [2,15]. Further outbreaks
occurred in India (1985), Mongolia (mid-1990), in
the Philippines (2004/2005), and again in India
s
e
t
Figure 3 Number of pilgrims visiting the Hajj in
Source: [41].the holy sites during Hajj.
2005). In South-East Asia, the serogroup A is pre-
ominant [2].
In the years 2003/04 and 2004/05 China saw
everal local outbreaks of meningococcal C dis-
ase. Vaccination campaigns appreciably reduced
he number of cases [16].
2005 and returning to their home countries.
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In Korea, the incidence of meningococcal disease
s, in general, very low, with serogroup Y predomi-
ating [17].
orth America
n the United States the serogroups B, C and Y
redominate, with serogroup Y gaining in impor-
ance. The incidence of meningococcal disease for
long time was between 1.0 and 1.5/100,000/year,
ut has decreased in recent years. In 2006, the
erogroups B and C caused most of the cases
serogroup B 28%, serogroup C 27%) [18]. Since
bout 1990, the proportion of serogroup Y cases has
ncreased greatly, and in 2008 was almost 40%.
Illustrative of the unpredictability of meningo-
occal epidemiology are the 14 cases of meningo-
occal disease caused by serogroup W135 that
ccurred in the south of Florida from December
008 to April 2009. Four of these 14 cases proved
atal, and one of the victims was a 26-year-old
ritish tourist [19].
outh America
hile the serogroups A and B predominate,
erogroup Y is becoming ever more important.
In Brazil, invasive meningococcal infections trig-
ered by serogroup C accounted for around 36%
n the years 1999—2002, and increased to 65% in
003/05 [20].
Between 1994 and 2006 approximately 78% of
ases in Columbia were caused by serogroup B,
ome 10% by serogroup C, and roughly 0.5% by
erogroup W135.
During this period, the ﬁgures for serogroups
, B and W135 showed little ﬂuctuation, but the
roportion of serogroup Y increased unexpectedly:
ffected cases rose from 0% in 1994 to 50% in
006. During this period, therefore, serogroup Y
as accountable for an average of 10% of the cases
21].
urope
erogroup B and C predominate, but A and W135
re on the increase.
Apart from epidemics, the incidence ranges from
pproximately 0.5/100,000/year in low incidence
ountries (Poland, Hungary, Italy) to approximately
/100,000/year in countries with higher incidence
Iceland, Ireland, Malta) [22]. Overall, serogroup B
s responsible for most cases (40—90%), followed by
erogroup C (0—55%), the course of which is usually
ore dramatic [22].
y
T
i
c147
In the past decades, Norway, Great Britain and
reland experienced repeated epidemic outbreaks
Norway serogroup B; Great Britain serogroup C)
22].
In Great Britain and Ireland, vaccination cam-
aigns and the introduction of the meningococcal
conjugate vaccine into the vaccination calen-
ar for children greatly reduced the incidence
f meningitis [23]. In the UK, the number of
ases of invasive meningococcal disease caused by
erogroup C declined from a high of 954 cases in
998/99 before vaccine introduction to 64 cases in
003/04 [24].
In Greece, between 1999 and 2003 serogroup B
redominated (60% of the cases). Serogroup A was
econd most frequent (19%), followed by serogroup
135 (11%) [25].
In 2005 and 2006, epidemiological studies in
urkey revealed an incidence of almost 43% for
erogroup W135 infection, 31.1% for serogroup B,
.2% for serogroup Y, and 0.7% for serogroup A [26].
In December 2007/January 2008 serogroup C
eningococci were responsible for two outbreaks in
taly. A total of nine people contracted the disease
nd three died [27].
ustralia and New Zealand
ver a period of a decade, New Zealand saw
severe epidemic triggered by serogroup B.
he annual incidence increased from 53 cases
1.6/100,000) in 1990 to a peak of 650 cases
17.4/100,000) in 2001 [28]. Thanks to a vaccine
pecially developed against this strain, the epi-
emic was brought under control: Since vaccine
ntroduction in 2004, incidence rates have dropped
o 2.6/100,000 in 2007, which is slightly higher than
he pre-epidemic level [29]
In Australia, the overall reported number of inva-
ive meningococcal disease has dropped from about
00 cases per year in 2003 to about 260—280 cases
relatively stable since 2006) [24]. Here serogroups
and C predominate. While in children below the
ge of 4 serogroup B is responsible for up to 99% of
he cases, in adults the percentage of serogroup B
anges between 10 and 30%. About 7% of all cases
re fatal [30].
he risk for traveling adolescents and
oung adults
he risk of becoming infected with meningococci
ncreases when many people come together under
rowded conditions (Fig. 4). This applies in par-
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and above [37]).Figure 4 The infection risk (incidence) as a function of
the social situation.
Adapted from [10].
ticular to adolescents and young adults. Pupils on
exchange programs, holiday/language courses or
practical courses (au pairs in host families), or
studying abroad, often come into close contact with
one another (lecture rooms, common rooms, dor-
mitories, refectories). Furthermore, young people
typically congregate together in their leisure time
(discotheques, concerts, parties), all venues asso-
ciated with close physical contact.
This group has an elevated risk of infection
(incidence 5—13/100,000 per year (Fig. 4)). A sim-
ilar situation pertains to army recruits, (incidence
2—5/100,000 per year (Fig. 4)). In 2007, 46 soldiers
in a military base in Warsaw became infected with
meningococci. Two died of fulminant sepsis despite
intensive medical care [31]. The meningococcus
is acquired through direct contact with respira-
tory droplets. In most cases, disease-causing strains
are acquired through close contact with an asymp-
tomatic carrier. Carriage, or colonization of the
upper respiratory tract mucosa, is a necessary but
not sufﬁcient cause of invasive disease.
In the USA, students and recruits are classiﬁed
as at particular risk when they spend most of their
time in the shared rooms mentioned above [32].
Immunization
A major feature of meningococcal epidemiology is
its unpredictability. One aspect of prophylaxis con-
sists of risk avoidance by personal behavior, e.g.
avoiding crowded conditions, cessation of smoking
and similar risk reduction. However, this is difﬁ-
cult to achieve and avoiding risks is not always
possible. Consequently, prophylactic immunization
makes good sense. Meningococcal vaccination can
b
c
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educe the individual risk of infection in travel-
rs. Furthermore, when a conjugate vaccine is
mployed, carrier rates — and thus global trans-
ission of the bacteria — can also be reduced, as
emonstrated for MenC [33].
It must, however, be noted that immunization
ecommendations in the home country will not nec-
ssarily ensure protection against meningococcal
nfection in other countries. The meningococcal
conjugate vaccine for children recommended
n many European countries offers no protec-
ion against other serogroups [33]. Before leaving
he country, travelers should therefore seek prior
dvice on available and recommended vaccines.
In many countries, including the Kingdom of
audi Arabia, in addition to meningococcal C
onjugate vaccine, a quadrivalent polysaccharide
accine is also available to all nationals and expa-
riates living in Hajj premises (Makkah and Medina),
eople performing Hajj or Umra, healthcare work-
rs and security personnel serving the pilgrims
uring the hajj as well as travelers. This latter,
lain polysaccharide vaccine, however, does not
onfer adequate protection, since its effect lasts
nly 3—5 years, it does not reliably reduce the car-
ier rate, and in infants aged less than 2 years
he polysaccharides of serogroups C, W135 and Y
re poorly immunogenic. Nor can the polysaccha-
ide vaccine prevent the spread of meningococci by
symptomatic carriers [34]. As well repeated dos-
ng with serogroup C polysaccharide vaccines may
nduce immune hyporesponsiveness [35].
Quadrivalent meningococcal conjugate vaccines
ffer advantages over plain polysaccharide vac-
ines. While their tolerability proﬁle is similar to
olysaccharide vaccines, they induce a stronger
mmune response [34]. Repeated doses with quadri-
alent meningococcal conjugate vaccines do not
esult in any weakening of the immune response
‘‘hyporesponsiveness’’) [35] but show a clear
ooster effect. They have the potential to reduce
he carrier rate, and therefore, they may con-
ribute to the reduction of bacterial transmission.
Until recently, the USA and Canada were the only
ountries to have licensed a quadrivalent meningo-
occal conjugate vaccine. In the USA this vaccine
s already recommended for all adolescents aged
1—18 years [32], and for all persons aged 2—55
ears at increased risk [36]. A further meningo-
occal ACWY conjugate vaccine has been recently
icensed in the USA (age 11—55) and the EU (age 11This year the Ministry of Health of Saudi Ara-
ia has introduced the quadrivalent meningococcal
onjugate vaccine for all children and adults from
ge 2—55 years who live in the Hajj premises,
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ilgrims from within Saudi Arabia, all healthcare
orkers and all government personnel serving the
ilgrims as the ﬁrst phase of their meningococ-
al disease prevention program. In this phase they
ill continue with the quadrivalent meningococ-
al plain polysaccharide vaccine for children below
years of age and adults above 55 years of
ge. In phase 2 of the program they will intro-
uce the quadrivalent conjugate meningococcal
accine to infants as part of the Expanded Pro-
ram of Immunization (EPI) of newborns, and adults
bove 55 years of age in the same risk cate-
ories mentioned earlier. In addition, people living
n non-hajj areas if they are frequent travelers
o Makkah and Medina or have special medical
ondition that predispose them to repeated or
evere meningococcal infections (e.g. asplenia and
ate complement deﬁciency), will be included in
he program. This second phase will be initi-
ted after the vaccine regulatory authorities grant
he needed approval for the quadrivalent conju-
ate meningococcal vaccine to be used in less
han 2-year-old children and above 55-year-old
dults.
Currently licensed conjugate meningococcal
accines include monovalent serogroup C conjugate
accines, as well as two quadrivalent (A, C, W-
35 and Y) conjugate vaccines. To date, only one
eningococcal conjugate vaccine using diphthe-
ia toxoid as the protein carrier has been licensed
or children 2—10 years of age, and the other
eningococcal conjugate vaccine using CRM197 as
arrier has been licensed for the age group above
5 [37].
ndications for meningococcal
accination in travelers
n assessing whether the meningococcal vaccination
s to be of beneﬁt for the international traveler,
areful assessment of the known risk factors for
isease acquisition must be made.
This assessment includes the traveler’s underly-
ng medical condition and the details of the planned
rip as it relates to the destination of travel, the
equired vaccination of that country, duration of
tay (high risk exists for long-term travelers) and
he expected activities (high risk exists for high
evel of contact with local population [e.g., sharing
rowded accommodation or transportation, work-
ng in the medical ﬁeld with extensive patient
ontact]). Travelers should be vaccinated with the
vailable quadrivalent meningococcal polysaccha-
ide or conjugate vaccines if they belong to any
C
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f the listed groups that signiﬁcantly increase their
isk of acquiring meningococcal disease.
Individuals should be vaccinated if they plan
ravels to countries or regions identiﬁed by
nternational health authorities to have active
eningococcal transmission (epidemic or hyperen-
emic areas), travelers for Umrah or Hajj (Hajj
ilgrims), travelers to high risk countries or regions
African meningitis belt countries) during the dry
eason (December—June) or countries in sub-
aharan Africa outside the meningitis belt (where
utbreak of meningitis has been reported in the
receding 2—3 years), military recruits or deployed
ilitary personnel, immunocompromized travelers
uch as those with asplenia or have terminal com-
lement deﬁciencies and high school and college
tudents.
However, limitations of prophylactic vaccination
re given when immediate protection is needed.
hen a patient is diagnosed with invasive meningo-
occal disease, contact persons should receive
hemoprophylaxis with antibiotics, as development
f an immune response physiologically takes time.
his includes household members as well as fel-
ow travelers. USA guidelines from the Centers for
isease Control and Prevention (CDC) recommend
hat chemoprophylaxis be considered for passen-
ers seated directly next to an index case on an
ircraft for at least 8 h [38].
onclusions
he epidemiology of meningococcal disease
xhibits remarkable diversity across the globe,
ith incidence rates ranging from less than 1
ase per 100,000 in many industrialized countries
o attack rates of 1% during meningitis belt epi-
emics. The battle against spread of travel-related
nfection specially meningococci in the setting of
ass migration is a shared one. Responsibilities
xtend beyond the host nation’s jurisdiction. The
isk of meningococcal infections and outbreaks can
e reduced if appropriate awareness and prophy-
actic measures are implemented before travel.
dentifying and preparing travelers at increased
isk for acquisition of meningococcal disease is the
ost effective strategy to prevent disease among
ravelers or their loved ones, especially with the
vailability of highly immunogenic novel conjugate
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